Janssen Pharmaceuticals

Part of Johnson & Johnson

Organisation

Trials

  • NCT06358638

    Collaborator, Phase 2, Recruiting, 12 people, 10 Apr 2024

  • NCT06083922

    Collaborator, Phase 2, Recruiting, 20 people, 16 Oct 2023

  • Improving HIV-1 Control in Africa With Long Acting Antiretrovirals

    Collaborator, Phase 3, Completed, 540 people, 19 Sept 2022

  • NCT05486481

    Collaborator, Phase 1/2, Withdrawn, 0 people, 3 Aug 2022

  • NCT04775550

    Collaborator, Phase 2, Active, not recruiting, 61 people, 1 Mar 2021

  • NCT04667663

    Collaborator, Phase 1, Active, not recruiting, 16 people, 16 Dec 2020

  • NCT04407442

    Collaborator, Phase 2, Terminated, 5 people, 29 May 2020

  • NCT04268498

    Collaborator, Phase 2, Active, not recruiting, 310 people, 13 Feb 2020

  • NCT03899155

    Collaborator, Phase 2, Recruiting, 1,500 people, 2 Apr 2019

  • NCT03556332

    Collaborator, Phase 2, Active, not recruiting, 41 people, 14 Jun 2018

  • NCT03450057

    Collaborator, Phase 2, Completed, 38 people, 1 Mar 2018

  • NCT03290950

    Collaborator, Phase 2, Active, not recruiting, 69 people, 25 Sept 2017

  • NCT03283917

    Collaborator, Phase 1, Completed, 21 people, 14 Sept 2017

  • NCT03093272

    Collaborator, Phase 2, Terminated, 9 people, 28 Mar 2017

  • NCT03063203

    Collaborator, Phase 2, Terminated, 17 people, 24 Feb 2017

  • NCT02955810

    Collaborator, Phase 1, Status unknown, 18 people, 4 Nov 2016

  • NCT02867020

    Collaborator, Phase 2, Completed, 128 people, 15 Aug 2016

  • NCT02207062

    Collaborator, Phase 2, Completed, 20 people, 1 Aug 2014

  • NCT02172872

    Collaborator, Phase 3, Status unknown, 606 people, 24 Jun 2014

  • NCT01905059

    Collaborator, Phase 3, Completed, 265 people, 23 Jul 2013

Sources: clinicaltrials.gov

Funded papers

Sources: pubmed.ncbi.nlm.nih.gov

Named in competing interests

Sources: pubmed.ncbi.nlm.nih.gov

Papers